Short Interest in Capricor Therapeutics Inc (NASDAQ:CAPR) Rises By 42.2%

Capricor Therapeutics Inc (NASDAQ:CAPR) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 7,950,000 shares, an increase of 42.2% from the December 15th total of 5,590,000 shares. Based on an average daily volume of 1,670,000 shares, the days-to-cover ratio is presently 4.8 days.

Analysts Set New Price Targets

CAPR has been the topic of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a report on Thursday, January 2nd. Maxim Group lifted their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. Piper Sandler started coverage on Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 price target for the company. Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Finally, Cantor Fitzgerald increased their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $34.50.

Hedge Funds Weigh In On Capricor Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp boosted its position in Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after buying an additional 9,040 shares during the last quarter. Rhumbline Advisers acquired a new position in shares of Capricor Therapeutics in the second quarter worth about $147,000. Renaissance Technologies LLC boosted its holdings in Capricor Therapeutics by 158.7% in the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 84,350 shares during the last quarter. Marshall Wace LLP acquired a new stake in Capricor Therapeutics during the 2nd quarter valued at approximately $426,000. Finally, SG Americas Securities LLC purchased a new stake in Capricor Therapeutics during the 3rd quarter worth approximately $133,000. 21.68% of the stock is owned by institutional investors and hedge funds.

Capricor Therapeutics Trading Up 7.0 %

Shares of CAPR traded up $0.88 during midday trading on Wednesday, reaching $13.47. 850,262 shares of the company were exchanged, compared to its average volume of 929,696. Capricor Therapeutics has a 1-year low of $3.52 and a 1-year high of $23.40. The stock has a 50-day moving average price of $15.68 and a 200-day moving average price of $11.43. The company has a market cap of $612.48 million, a price-to-earnings ratio of -12.71 and a beta of 4.08.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.